Rocket Pharmaceuticals (RCKT) Current Leases (2019 - 2026)

Rocket Pharmaceuticals (RCKT) has 8 years of Current Leases data on file, last reported at $1.9 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases rose 91.45% year-over-year to $1.9 million; the trailing twelve-month figure through Mar 2026 stood at $1.9 million (up 91.45% YoY), and the FY2025 full-year result was $1.0 million, changed 0.2% from the prior year.
• Current Leases improved to $1.9 million in Q1 2026, from $1.0 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $1.9 million in Q1 2026 to a low of $634000.0 in Q3 2022.
• A 5-year average of $1.3 million and a median of $1.1 million in 2024 frame the typical range for Current Leases.
• Across the five-year window, Current Leases jumped 179.65% in 2023 and plunged 44.11% in 2024, its largest moves.
• Tracing RCKT's Current Leases over 5 years: stood at $1.7 million in 2022, then increased by 3.17% to $1.8 million in 2023, then sank by 44.11% to $1.0 million in 2024, then gained by 0.2% to $1.0 million in 2025, then surged by 92.02% to $1.9 million in 2026.
• Business Quant data shows RCKT's Current Leases at $1.9 million in Q1 2026, $1.0 million in Q4 2025, and $1.9 million in Q3 2025.